anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a concentrated clear solution containing cerebral metabolism improving medicine for intravenous injection after pyrithioxin is diluted, which comprises salt pyrithioxin as an active compound, a mixed solvent and a medicinal formulation auxiliary material. Per milliliter concentrated clear solution contains 0.01 to 0.2 gram of active compounds. The mixed solvent is mainly composed of a mixture of ethanol and glycerol, or is mainly composed of a mixture of the ethanol and propanediol. The dosage of the mixed solvent enables the active compounds to dissolve and maintain the stabilization of the physicochemical properties of the mixed solvent. The concentrated clear solution containing cerebral metabolism improving medicine for intravenous injection is directly added into large-capacity infusion when used in clinical. Thus, the damage of particulate matters for patients is fundamentally avoided.
This study will recruit individuals with known BRCA1 and BRCA2 mutations or mutations in similar cancer causing genes such as CHK2 or PALB2 who have had a cancer removed by surgery or biopsied two or more times with available pathological blocks. We wish to enroll individuals who have had more than one surgery or biopsy for cancer allowing us to obtain tumor blocks from more than one time point. Such patients would include those with one cancer which has recurred or more than one separate cancer. We will conduct a brief interview with the subject to obtain personal information about medical and treatment history. In addition, we will collect clinical information from their treating physician(s) to correlate molecular findings with clinical responses to treatment and survival and recurrence data. We will collect background clinical information and family history information and a copy of the genetic test results documenting their cancer causing mutation. We will recruit only patients with known BRCA1 or BRCA2 mutations or known mutations in other cancer causing genes such as CHK2 or PALB2 and will not perform genetic testing on non-tumor tissue for any new information on genetic susceptibility in patient samples. Enrolled subjects will donate a blood sample that will be obtained locally and shipped to the research laboratory, and this cost will be entirely covered by the research group.
FIELD: veterinary science, microbiology. SUBSTANCE: invention relates to method of immunoenzyme diagnosis of brucellosis in agriculture animals. For sensibilization of polystyrene plate inactivated corpuscular antigen from the strain Y. enterocolitica, serovariant 0:3, is used additionally. Both this antigen and inactivated corpuscular antigen from the strain Br. abortus 19 are added into polystyrene plate wells being each antigen is added into one of its half in buffered physiological solution (pH = 7.3, optical density is 0.1 O.U. by turbidity at wave- -length 540 nm in cuvette 10 mm). Sensibilization of polystyrene plate is carried out by its incubation at 37 C for 15 min. The novel test-system provides differentiation of cattle brucellosis from intestine yersiniosis caused by Yersinia enterocolitica, serovariant 0:9. EFFECT: enhanced sensitivity and specificity, decreased labor intensity, increased effectiveness of analysis for brucellosis. 6 tbl, 6 ex
1. Antitussive pharmaceutical composition comprising as active ingredient a therapeutically active amount of theobromine of the formula (III)   and/or its salts and/or its complexes optionally in admixture with inert, solid or liquid carriers, additives and auxiliary agents. 2. Composition according to claim 1, being in the form of injection, syrup, dragee, tablet, pastille, suppository, capsule and retard form of them, preferably in the form of liposome. 3. Use of theobromine of the formula (III) and/or its salts and/or its complexes optionally in admixture with inert, solid or liquid carriers, additives and auxiliary agents for the manufacture of an antitussive pharmaceutical composition. 4. Use of theobromine of the formula (III) and/or salts and/or its complexes optionally with inert, solid or liquid carriers, additives and auxiliary agents according to claim 3, for the manufacture of an antitussive pharmaceutical composition being in the form of injection, syrup, dragee, tablet, pastille, suppository, capsule and retard form of them, preferably in the form of liposome. 5. Method of treatment of a human or animal subject which comprises the step of administering in an antitussive effective amount theobromine (III) and/or its salts and/or its complexes optionally in admixture with inert, solid or liquid carriers, additives and auxiliary agents. 6. Method of treatment according to claim 5. using theobromine of the formula (III) and/or its salts and/or its complexes in the form of injection, syrup, dragee, tablet, pastille, suppository, capsule and retard form of them, preferably in the form of liposome.
Although an emulsion prepared by emulsifying l-menthol with an emulsifier alone remains stable within several hours after the preparation, l-menthol therein is then gradually separated out and migrates towards the surface. As l-menthol is separated out from the emulsion as described above, the component distribution in the emulsion becomes uneven. When such an emulsion is sprayed as a peristalsis controller onto, for example, the stomach wall, no constant effect can be achieved and, therefore, it is required to prepare the emulsion immediately before using. An oil-in-water emulsion of l-menthol which remains stable without suffering from the separation of l-menthol can be obtained by mixing l-menthol with a fatty acid, a fatty acid ester or a mixture thereof, an emulsifier and water and then emulsifying. When directly sprayed to, for example, the inside of a digestive tract, this emulsion immediately and continuously exhibits its effect of controlling the peristalsis. It can be safely used for a subject under contraindications for the use of scopolamine butyl bromide, for example, a patient with glaucoma.
PURPOSE: To provide an oxidative dyeing method and compsn. for the human hair which do not damage the hair. CONSTITUTION: This compsn. contains an oxidation dyeing precursor, peroxides not contg. catalase and an oxidizing agent compd. more particularly a second compsn. contg. hydrogen peroxide of a decreased concn. of about 0.01 to 1 wt.% when calculated as the hydrogen peroxide for the total compsn. in a state of mixing and this method consists in gently dyeing the human hair with the compsn. The components of the second compsn. are previously mixed or are separately preserved before application and thereafter, the hair dyeing mixture produced in the manner described above is applied to the hair. Two kinds of the components may be applied successively on the hair.
FIELD: biotechnology. SUBSTANCE: invention relates to medicinal preparations containing substances of unknown structure produced by bacteria and development of immunostimulating preparation based on lactic acid bacteria. Strains Streptococcus faecium 3185-M B-349 and Streptococcus faecium M VKPM B-3490 were taken as strains of lactic acid bacteria and produced as dry concentrate of monocultures and mixed at ratio = (0.6-1.4):(0.6-1.4) by viable cells amount. Preparation shows high biological activity involving immunostimulating activity, inhibits pathogenic and opportunistic microflora and has no serum immunoglobulins. Preparation enhances immune status, resistance, stress resistance and adaptation capability of human and animal organism. EFFECT: enhanced effectiveness of preparation.
BACKGROUND: Tendon-bone interface (TBI) healing in chronic rotator cuff injury (CRCI) in older individuals is a common clinical challenge due to cellular senescence, as well as decreased tissue repair and regeneration. Many studies have demonstrated the antiaging, improved tissue repair, and bone regeneration properties of rapamycin (RPM) in multiple age-related diseases. This study aimed to explore the effects of RPM on TBI healing after CRCI in an aging rat model.
METHODS: A CRCI model was established in 60 Sprague-Dawley rats (24 months old). Rats were then randomly allocated into the control, 0.1 μg RPM, and 1 μg RPM groups. At 4 and 8 weeks postreconstructive surgery, the supraspinatus tendon-humerus complexes were harvested for biomechanical, microimaging, histological, and immunohistochemical evaluations.
RESULTS: Biomechanical testing results demonstrated that the failure load, ultimate strength, and stiffness of the 2 RPM groups were significantly higher than those of the control group at 4 and 8 weeks postoperatively. Microradiographically, both RPM groups had significantly higher values of bone mineral density and the ratio of trabecular bone volume to total volume than controls at each time point. Moreover, the RPM groups had higher histological scores and showed better regenerated TBI, characterized by better organizational tissue, more fibrocartilage cells, and more bone formation. Immunohistochemical evaluations showed that RUNX2-, SOX9-, and SCX-positive cells were significantly more in the 2 RPM groups than in the controls at each time point.
CONCLUSIONS: RPM may effectively enhance CRCI healing after reconstruction by facilitating osteogenesis, tenogenesis, and fibrocartilage reformation at the TBI, as well as improving biomechanical properties.
A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins.  The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic method for a malignant tumor in which a cell-specific expression replication vector is constructed in order to treat the malignant tumor by expressing and replicating a gene in a specific cell, for example, that of the malignant tumor while normal cells may not be damaged, wherein the vector is transferred into the specific living cell, e.g. the malignant tumor cell, and expressed for treatment.  <P>SOLUTION: A transcription initiation control region of human calponin gene specifically expressed in a cell is acquired and linked to the upstream portion of a replication-related gene for a virus, e.g. ICP4. A DNA encoding the protein of vascularization inhibitory factor or apoptosis-relating factors is linked through IRES to the replication-related gene for the virus, while a thymidinekinase gene is left intact. The resultant DNA sequence is incorporated into a virus DNA to construct the cell-specific expression replication vector and the constructed vector is infectively transferred into the malignant tumor cell to selectively break the tumor cells.  <P>COPYRIGHT: (C)2003,JPO
NEW MATERIAL:The compound of formula I [A is single bond, 1-8C alkylene or 2-8C alkenylene; R is 1-20C alkyl or group of formula II (B is single bond or O; R<1> is H, halogen, 1-4C alkyl, 1-4C alkoxy or nitro; n is 1-15)]. EXAMPLE:N-[3-(4-methylphenyl)propionyl]-L-prolinal. USE:A drug. An active component for antiamnestic agent. It has prolyl endopeptidase-inhibiting activity and low toxicity and is expected to be useful for the prevention and remedy of amnesia. PREPARATION:The objective compound of formula I can be produced by reacting prolinol of formula III with an acid of formula IV to form an amide bond and oxidizing the resultant prolinol derivative of formula V under mild condition in an inert solvent (e.g. dimethyl sulfoxide) in the presence of an oxidizing agent (e.g. sulfur trioxide-pyridine complex) and optionally a tertiary amine (e.g. triethylamine) at 0-50 deg.C.
1. Technical Result Increase in treatment efficiency of the diseases caused by protease activity. 	  2. Essence A composition of the formula wherein R and R1, have the values indicated in the description; the mentioned compounds are HIV protease inhibitors, which inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate; pharmaceutical compositions containing the same and methods for inhibiting.          3. Field of Application Medicine.
Background: Matrix metalloproteinase (MMP) enzyme gene polymorphisms MMP-2-1575G/A and MMP-9-1562C/T promoter polymorphism, their serum levels, and activity are associated with aortic valve calcification (AVC). Materials and Methods: The synergistic link between the risk of AVC and the alleles T and A of MMP-9 and MMP-2 was investigated, respectively. Ninety-two cases with AVC and 92 healthy individuals from the west of Iran were included, and MMP- 2-1575G/A and MMP-9-1562C/T promoter polymorphisms were detected using PCR-RFLP. The serum levels and activity of MMP-2 and -9 were assessed using ELISA and gelatin zymography methods, respectively. In addition, serum biochemical markers, including FBS, urea and creatinine, cholesterol, triglyceride, HDL, LDL, calcium, phosphorus, and blood pressure: systolic blood pressure and diastolic blood pressure were measured. Results: Heart valve calcification disease was associated with a comparatively higher frequency of the A allele of the MMP2-1575 variation (p = 0.002). In addition, the frequency of T allele of the MMP9-1562 variant was higher than the control group (p = 0.007). Conclusion: MMP-2 and MMP-9 serum levels and activities were observed to be considerably higher in the experimental group than in the control group (p < 0.001). Patients are more susceptible to cardiovascular disease than the control group due to elevated serum levels and activity of MMP-2 and MMP-9.
The invention provides a POCT (point of care testing) personalized data processing method and application, comprising the steps of setting a processing module into a module comprising a storage unit, a comparison unit and a calculation unit, and setting a database and a timer. The method also comprises the steps of setting triggering standard and execution rule of data processing in the timer. The method also comprises the step of updating project information of the project in the database. The method also comprises the step of giving each user an account number, and the personalized information can be updated by logging in the account number. The method also comprises the step of acquiring a signal for triggering the data processing flow through an interaction module or a detection reagent identification module or a processing module. According to the invention, the personalized information is combined with the standards and rules for synchronizing and cleaning the project information through the personalized processing method, so that the privacy of the patient is protected, the information comparison amount during detection is reduced, the working efficiency is improved, the network communication frequency is reduced, the data processing is more intelligent, and the user experience is improved.
Military burn pits, used for waste disposal in combat zones, involve the open-air burning of waste materials, including plastics, metals, chemicals, and medical waste. The pits release a complex mixture of occupational toxic substances, including particulate matter (PM), volatile organic compounds (VOCs), heavy metals, dioxins, and polycyclic aromatic hydrocarbons (PAHs). Air pollution significantly impacts brain health through mechanisms involving neuroinflammation. Pollutants penetrate the respiratory system, enter the bloodstream, and cross the blood-brain barrier (BBB), triggering inflammatory responses in the central nervous system (CNS). Chronic environmental exposures result in sustained inflammation, oxidative stress, and neuronal damage, contributing to neurodegenerative diseases and cognitive impairment. Veterans exposed to burn pit toxins are particularly at risk, reporting higher rates of respiratory issues, neurological conditions, cognitive impairments, and mental health disorders. Studies demonstrate that Veterans exposed to these toxins have higher rates of neuroinflammatory markers, accelerated cognitive decline, and increased risks of neurodegenerative diseases. This narrative review synthesizes the research linking airborne pollutants such as PM, VOCs, and heavy metals to neuroinflammatory processes and cognitive effects. There is a need for targeted interventions to mitigate the harmful and escalating effects of environmental air pollution exposures on the CNS, improving public health outcomes for vulnerable populations, especially for Veterans exposed to military burn pit toxins.
Melphalan, is a bifunctional alkylating drug that is active against selected human neoplastic diseases. Melphalan is available as melphalan hydrochloride salt. The chemical name of melphalan hydrochloride is 4-[bis(2-chloroethyl)amino]-L-phenylalanine hydrochloride. The molecular formula is C13H18Cl2N2O2.HCl and the molecular weight is 341.67. 

Melphalan is practically insoluble in water and has a pKa1 of ~2.5. 

HEPZATO, for injection, is supplied as a sterile, nonpyrogenic, freeze-dried white to pale yellow freeze-dried cake/ powder. Each single dose vial contains melphalan 50 mg, equivalent to 56 mg of melphalan hydrochloride and 20 mg povidone. 

HEPZATO (melphalan) is reconstituted using the sterile diluent provided. Each vial of sterile diluent contains sodium citrate 0.2 g, propylene glycol 6.0 mL, ethanol (96%) 0.52 mL, and water for injection to a total of 10 mL. 

HEPZATO (melphalan) for use with the hepatic delivery system is administered intra-arterially.
You are being asked to take part in this research study because you have been scheduled to have a scan of your heart. The radioactive dye used to image your heart is also taken up by many types of breast cancer. The investigators have developed a new method for detecting breast cancer, called Molecular Breast Imaging that uses this dye.

The purpose of this study is to see how well this new method works in normal subjects with no known breast cancer and to see if we can detect breast cancer at an earlier stage than mammography. As you read this form describing the study, ask any questions you have. Take your time to decide. Feel free to discuss the study with your family, friends, and healthcare provider before you decide. You may stop participating at any time during the study. You may decide not to participate. If so, none of your current benefits or normal health care will be affected in any way. When you feel comfortable that all your questions have been answered, and you wish to take part in this study, sign this form in order to begin your participation. Your signature means you have been told about the study and what the risks are. Your signature on this form also means that you want to take part in this study.
Patients participate in interviews up to 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.
FIELD: cosmetology. SUBSTANCE: invention relates to cosmetic agents containing biologically active natural substances, namely, to complexes of biologically active components from algae. Cosmetic agent comprises product produced from laminaria and at least one cosmetic supplement. Agent comprises biogel from laminaria japonica as product produced from laminaria. Foodstuff product "Lamidan" producing from laminaria japonica is used as biogel from laminaria japonica. Agent comprises 50% an aqueous solution of glycolic acid as a cosmetic supplement. Ratio of biogel from laminaria japonica and an aqueous solution of 50% glycolic acid can be = (1.5-15):1 (60-94 wt.-% of "Lamidan", 6-40 wt. -% of glycolic acid). Ratio of biogel from laminaria japonica and an aqueous solution of 50% glycolic acid can be = 2:1. Cosmetic agent exfoliates off cornea layer of thickened epidermis, enhances collagen production and reconstruction of elastic fibers, derma thickening, improves hydration and deep skin nutrition with trace elements. EFFECT: enhanced effectiveness and valuable medicinal and cosmetic properties of agent. 6 cl, 5 ex
Self-renewal and differentiation are two characteristics of hematopoietic stem cells (HSCs). Under steady physiological conditions, most primitive HSCs remain quiescent in the bone marrow (BM). They respond to different stimuli to refresh the blood system. The transition from quiescence to activation is accompanied by major changes in metabolism, a fundamental cellular process in living organisms that produces or consumes energy. Cellular metabolism is now considered to be a key regulator of HSC maintenance. Interestingly, HSCs possess a distinct metabolic profile with a preference for glycolysis rather than oxidative phosphorylation (OXPHOS) for energy production. Byproducts from the cellular metabolism can also damage DNA. To counteract such insults, mammalian cells have evolved a complex and efficient DNA damage repair (DDR) system to eliminate various DNA lesions and guard genomic stability. Given the enormous regenerative potential coupled with the lifetime persistence of HSCs, tight control of HSC genome stability is essential. The intersection of DDR and the HSC metabolism has recently emerged as an area of intense research interest, unraveling the profound connections between genomic stability and cellular energetics. In this brief review, we delve into the interplay between DDR deficiency and the metabolic reprogramming of HSCs, shedding light on the dynamic relationship that governs the fate and functionality of these remarkable stem cells. Understanding the crosstalk between DDR and the cellular metabolism will open a new avenue of research designed to target these interacting pathways for improving HSC function and treating hematologic disorders.
OBJECTIVES: To investigate the role of systemic immune-inflammation index (SII) in the diagnosis and severity of intrahepatic cholestasis of pregnancy (ICP).
METHODS: This case-control research involved 173 pregnant women with ICP and 266 gestational age-related healthy pregnant women as the control group. Criteria for diagnosing ICP were acceptance of increased serum total bile acid (TBA) levels (≥10 μmol/L). The mild ICP group (n=109) had TBA levels ranging between 10-39 µmol/l, while the severe ICP group (n=64) had a minimum TBA level above 40 µmol/l. Sociodemographic data, laboratory results, and SII values were compared between groups. Cut-off values were calculated to predict ICP. The SII was calculated as the platelet count × neutrophil count/lymphocyte count.
RESULTS: The leukocyte and neutrophil counts were lower (p<0.01), and the monocyte count was higher (p=0.026) in the severe ICP group compared to the controls. The platelet-to-lymphocyte ratio (PLR) was higher in mild ICP groups than in controls (p<0.01). The optimum PRL cut-off value was 126.2238, with a sensitivity of 57.2% and specificity of 57.1%.
CONCLUSION: Elevated SII values support the evidence for the inflammatory properties of ICP but do not aid in diagnosing and determining its severity. Platelet-to-lymphocyte ratio may be a useful marker in determining ICP.